

7. BENEFITS & EXCLUSIONS

7.1 Benefits

The Program provides a wide range of drug benefits. Items included as benefits are determined by the Minister.

The Coverage Status Table is updated monthly and is available for review or can be downloaded from the Program web site at http://www.health.gov.nl.ca/health/prescription/coverage_status_table.pdf. The listing identifies benefit items of the Program.

The table consists of the following columns:

- DIN
- Label Name
- Benefit Status (indicates Open Benefit or Special Authorization)
- Limitation (indicates Benefit Limitation if one is applicable and none if a Benefit does not have a limitation)
- NIDPF (Newfoundland and Labrador Interchangeable Drug Products Formulary – indicates Y if listed in the Formulary or N if not)
- Package Size
- NLPDP List Price
- NIDPF Manufacturers' List Price ("MLP") (Newfoundland and Labrador Interchangeable Drug Products Formulary)

7.2 Benefit Exclusions

The Program will not provide payment for certain items including:

- Prescription cough syrups and medicines for cough and cold symptoms unless specified on the Benefit List
- Over-the-Counter (OTC) medications unless specified on the Benefit List
- Delivery, Postal or C.O.D. charges

- Any benefit item for which the resident is entitled to under Workers Compensation or federally funded program
- Single doses of injectables or other medications provided or administered by a doctor or dentist in the course of a home or office visit unless specified
- Prosthetics such as hearing aids, eye glasses, dentures, splints or orthotics
- First aid supplies, dressings
- Dietary supplement and food products unless specified
- Cosmetics, soaps, dental and beauty aids
- Oxygen
- Allergy Serums
- Drugs not authorized for sale and use in Canada (e.g. drugs obtained through Health Canada's Special Access Program, experimental or investigational drugs)
- Cannabis or cannabis products
- Products for the treatment of erectile/sexual dysfunction
- Diagnostic agents and point-of-care testing kits
- Medical supplies, devices and equipment (e.g. blood glucose monitors)
- All products not identified as benefits

7.3 The Newfoundland and Labrador Interchangeable Drug Products Formulary

The Newfoundland and Labrador Interchangeable Drug Products Formulary (NIDPF) is a list of commonly used drugs which have therapeutic equivalence to and have the same route of administration as a reference product. For more information on the NIDPF, please refer to

<https://www.health.gov.nl.ca/health/prescription/idf.html>

7.4 Drug Benefit Review Process

All drugs considered for benefit status under the Program are subject to a review by the Canadian Drug Expert Committee (CDEC), the Atlantic Expert Advisory Committee (AEAC) or the Pan-Canadian Oncology Drug Review Expert Committee (pERC), as the case may be.

For more information on the Drug Benefit Review Process please see Appendix C.

7.5 Special Authorization Status Drugs

If a Prescriber wishes his/her patient to receive a product that is not listed on the Coverage Status Table, or is listed but is indicated as requiring Special Authorization, the Health Care Professional must contact the Program on behalf of his/her patient with a request for Special Authorization documenting medical need. The Beneficiary and the requesting Prescriber will receive written notification of the Program's decision.

When a claim for a Special Authorization is successfully adjudicated by the Program system, a message will be returned to the Provider indicating the quantity and time remaining on the authorization. This will provide the opportunity to notify a Beneficiary whose authorization is close to expiry.

Information regarding the Special Authorization Process can be reviewed in Appendix D.

The criteria for coverage of Special Authorization medications and Special Authorization Request Forms are available online at:
<http://www.health.gov.nl.ca/health/nlpdp/criteria.pdf>

Policy Amendment History

| | <i>Effective Date</i> |
|-----------------|-----------------------|
| Original Policy | November 30, 2011 |
| Revision # 5 | November 2020 |